Adocia SA (0QAI.L)

8.32 -0.43 (-4.91%) As of 08:00AM BST. Market open.

Adocia SA

115 Avenue Lacassagne
Lyon 69003
France
33 4 72 61 06 10
https://www.adocia.com

Sector(s): 
Industry: 
Full-time employees: 97

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Gérard Soula M.B.A., Ph.D.	Co-Founder & Chairman of the Board	370.62k	N/A	1945
Mr. Olivier Soula M.B.A., Ph.D.	Co-Founder, CEO & Director	278.63k	N/A	1970
Ms. Valérie Danaguezian	Chief Financial Officer	N/A	N/A	N/A
Jeremy Benattar Eng., Pharm.D.	Marketing & Strategy Director	N/A	N/A	N/A
Ms. Geraldine Favre Soula	Human Resources Development Director	N/A	N/A	N/A
Dr. Bertrand Alluis	Head of the Analysis Department and Project Manager	N/A	N/A	N/A
Dr. David Duracher	Head of the Pharmaceutical Development & Physical Chemistry Departments and Project Manager	N/A	N/A	N/A
Dr. Richard Charvet	Head of Chemistry Department & Project Manager	N/A	N/A	N/A
Dr. Grégory Meiffren	Head of the Biology Department & Project Manager	N/A	N/A	N/A
Rosy Eloy M.D.	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and BioChaperone GluExe, a combination of glucagon and exenatide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.

Corporate governance

Adocia SA’s ISS governance QualityScore as of 1 April 2024 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 9; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.